Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Leveraging AI to Improve Patient Outcomes in Healthcare

The importance of providing patients with a fast and accurate diagnosis cannot be overstated – it can be the difference between life and death. Unfortunately, the healthcare system is overwhelmed, and physicians cannot keep up with the overflow of patient needs in a timely manner. Dr. Chai Xiangfei, CEO and co-founder at HY Medical, and…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Promoted content from Intel on MarketScale.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

The importance of providing patients with a fast and accurate diagnosis cannot be overstated – it can be the difference between life and death. Unfortunately, the healthcare system is overwhelmed, and physicians cannot keep up with the overflow of patient needs in a timely manner.

Dr. Chai Xiangfei, CEO and co-founder at HY Medical, and Beenish Zia, chief architect of medical imaging at Intel, sit down with podcast host, Tyler Kern, to discuss the current challenges of providing a patient diagnosis in a timely manner and how artificial intelligence (AI) solutions can help.

Beenish discusses and highlights the complexities of diagnosing patient illnesses. “Medical diagnosis is a complex process which requires clinical skills and the need for clear decisions. And it needs to be balanced with acceptance for the ambiguity of many clinical situations,” Beenish explains.

According to Beenish, there are five major obstacles that delay diagnosis:

  1. There are variations in individual logic and processes.
  2. Because the nature of the evidence is not clear, further tests/screenings are required.
  3. Standards vary globally, which causes longer diagnosis times.
  4. Lack of evidence and data from diverse populations leads to not having good data sets to represent different communities.
  5. The number of cases a physician must handle grows daily.

“For example, in certain hospitals in New York, we have heard that the radiologists get more than 1400 scans per day, and maybe there is just like a handful of radiologists to look at them. So, just the huge imbalance between the number of cases requiring diagnosis and the medical staff available to provide the diagnosis is not good,” Beenish explains.

To address this need, Dr. Chai talks about the role of AI in reducing diagnosis time to improve patient outcomes. “There are a huge amount of images created every day. In the meantime, actually, there’s a shortage of radiologists to read images. So, the real situation is that because there is a long waiting list of imaging… it can take hours or even days” for patients to get the result of their tests, notes Dr. Chai.

With traditional processes, scans are taken and added to a waiting list to be read and interpreted by radiologists, which can take up to 15 minutes. Current AI technology can give initial results within one minute and can ultimately reduce reading time by 30%. When radiology staff and doctors get the initial results, they can then quickly review the areas highlighted by the AI and then determine a path forward for diagnosis and treatments. Having this reduction in reading time, is helping patients get treated sooner.

To learn more about how AI can transform the diagnostic process and improve patient outcomes, connect with Dr. Chai Xiangfei and Beenish Zia on LinkedIn.

To find out more about HY Medical please visit: https://www.huiyihuiying.com/#page1.

Learn about various technologies Intel offers to advance the healthcare field — from compute to storage and networking to AI — visit: https://www.intel.com/content/www/us/en/healthcare-it/healthcare-overview.html

Subscribe to this channel on Apple Podcasts, Spotify, and Google Podcasts to hear more from the Intel Internet of Things Group.

Intel

Part of this channel

Intel

Silicon and AI platforms powering enterprise and edge compute.

Visit the channel

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended AstraZeneca and Daiichi Sankyo’s Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly is investing $6.5 billion in a Houston manufacturing facility set to open around 2030, primarily to scale production of Foundayo, its oral GLP-1 treatment. The project signals a broader shift in U.S. pharmaceutical manufacturing reshoring and underscores the supply chain challenge of forecasting demand and building capacity years in advance for breakthrough therapeutics.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain: Lilly's CEO noted that one-third of new GLP-1 pill patients are now choosing Foundayo, illustrating fast-moving market share shifts that complicate production planning years in advance
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

Waiting for perfectly clean data is stalling healthcare AI, not protecting it

Healthcare organizations often delay AI initiatives waiting for perfectly clean data, but this assumption no longer holds: reliable subsets and synthetic data allow projects to start now while data work continues in parallel. Success requires starting with business outcomes rather than technology capabilities, and embedding governance in product strategy before implementation, not after.

  • 01Waiting for 100% clean data is effectively a decision never to start; hospital AI projects can begin on reliable data subsets while quality work continues in parallel.
  • 02Frame AI decisions around business outcomes (revenue growth, cost reduction, competitive advantage, new products, or ecosystem influence) rather than asking what AI can do.
  • 03Governance should be part of product strategy before design or purchase, especially as agentic AI takes actions—such as handling many revenue-cycle denials—while routing the rest to humans.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512